Oscar Health Reports Revenue Growth And Expansion

On January 9, UBS upgraded Oscar Health (NYSE: OSCR) to Neutral and raised its price target to $17 from $12. In Q3 2025 Oscar reported 23% year-over-year revenue growth to about $3.0 billion and a medical-loss ratio of 88.5% (up 380 basis points). Management plans 2026 expansion into 20 states, new products like HelloMeno, and AI integration via Oswell.
Scoring Rationale
Credible, timely company results and analyst upgrade drive relevance; limited novelty and single-company focus constrain broader impact.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems

